Law M, Cheng K C, Wu P M, Ho W Y, Chow L W C
Departments of Clinical Oncology and Surgery, Nuclear Medicine Unit, Queen Mary Hospital, 102 Pokfulam Road Hong Kong.
Br J Radiol. 2003 Nov;76(911):818-23. doi: 10.1259/bjr/57254925.
The aim of this study was to measure the dose delivered to patients undergoing sentinel lymph node lymphoscintigraphy by taking into account both the transmission scan dose using a (57)Co flood source and the (99)Tc(m) internal emission dose. An adult female humanoid phantom and a set of thermoluminescent dosimeters were used in the measurements. The choice of measurement organs in the humanoid was guided by the recommendations described in the International Commission on Radiological Protection report number 60. A (57)Co flood source was used in external transmission to irradiate the humanoid at posterior, left lateral, left posterior oblique, right lateral and right posterior oblique positions. Four (99)Tc(m) deposits as internal emission sources were used to simulate patient peritumoural injection. The individual effective doses for external transmission and internal emission, normalized to the cumulated activity and expressed in micro Sv(MBq x h)(-1) were then calculated. The effective dose for a transmission scan was on average 0.061 micro Sv(MBq x h)(-1) for each (57)Co flood source position and for internal emission 0.312 micro Sv(MBq x h)(-1) and 0.291 micro Sv(MBq x h)(-1) for left and right breast injection, respectively. Using these results, the effective dose from both transmission and emission sources can be calculated according to the nuclear medicine scanning protocol and surgical procedure of the individual institution. For our protocols, the patient receives a maximum effective dose of 52 micro Sv for the 1 day protocol (18 MBq injection) and 204 micro Sv for the 2 day protocol (74 MBq injection) if only the sentinel lymph node is excised. If other tissues containing radioactivity are removed, the patient effective dose will be reduced by about 50% and 6%, respectively, for the 1 day protocol and 2 day protocol. Although the doses are low compared with other radiological examinations, the results are informative for patients concerned about radiation exposure for this new imaging technique.
本研究的目的是通过同时考虑使用(57)Co泛源的透射扫描剂量和(99)Tc(m)内照射剂量,来测量前哨淋巴结淋巴闪烁成像患者所接受的剂量。测量中使用了一个成年女性人体模型和一组热释光剂量计。人体模型中测量器官的选择遵循国际放射防护委员会第60号报告中的建议。使用(57)Co泛源进行外部透射,在人体模型的后位、左侧位、左后斜位、右侧位和右后斜位进行照射。使用四个作为内照射源的(99)Tc(m)沉积物来模拟患者肿瘤周围注射。然后计算归一化到累积活度并以微Sv(MBq×h)(-1)表示的外部透射和内照射的个体有效剂量。对于每个(57)Co泛源位置,透射扫描的有效剂量平均为0.061微Sv(MBq×h)(-1),对于内照射,左乳和右乳注射的有效剂量分别为0.312微Sv(MBq×h)(-1)和0.291微Sv(MBq×h)(-1)。利用这些结果,可以根据各机构的核医学扫描方案和手术程序计算透射源和发射源的有效剂量。对于我们的方案,如果仅切除前哨淋巴结,患者在1天方案(18 MBq注射)中接受的最大有效剂量为52微Sv,在2天方案(74 MBq注射)中接受的最大有效剂量为204微Sv。如果切除其他含有放射性的组织,对于1天方案和2天方案,患者的有效剂量将分别降低约50%和6%。尽管与其他放射学检查相比剂量较低,但这些结果对于担心这种新成像技术辐射暴露的患者来说是有参考价值的。